Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...

It's one of the top healthcare stocks in my portfolio. If I didn't already own this biotech stock, I wouldn't hesitate to buy ...

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

In December 2023, through the development efforts of CRISPR Therapeutics and Vertex Pharmaceuticals, their decades-long ...

CRISPR Therapeutics (CRSP) stock slips after a strong rally driven by earnings beats and analyst upgrades. Explore future catalysts and investment insights.

Casgevy, a gene therapy for sickle cell disease and beta thalassemia developed with Vertex Pharmaceuticals, has had a fairly slow rollout, but its launch seems to be gaining momentum. Fifty ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...